2. Select Ongoing Neoadjuvant Immunotherapy Trials Adjuvant Immunotherapy A number of completed and ongoing trials are solely looking at adjuvant immunotherapy involving each of the major ICIs ( Table 3 ). The only large adjuvant study
Search Results
Page:12
Bharathi Muthusamy, Pradnya D. Patil, and Nathan A. Pennell
Paul B. Chapman
High dose interferon-α (HD IFN) is approved by the United States Food and Drug Administration for adjuvant treatment of patients with stage III melanoma after complete surgical resection. Despite this, clinicians and patients around the world and in many parts of the US have failed to embrace this treatment option because of the lack of overall survival benefit and minimal other clinical benefits seen in randomized trials, combined with the therapy's substantial toxicity. This article reviews the data from the randomized trials that lead to this conclusion and discuss why arguments often advanced in favor of using HD IFN are not persuasive. New treatment options are needed for adjuvant therapy of melanoma. In the meantime, the data from the randomized trials make it difficult for many clinicians and patients to have enthusiasm for adjuvant HD IFN.
Presented by: Philippe E. Spiess, Peter A.S. Johnstone, and Eric Jonasch
experienced disease progression. Most studies of adjuvant tyrosine kinase inhibitors (TKIs) for high-risk localized RCC with clear cell histology have been negative, but adjuvant immunotherapy has shown promise. Several negative studies of adjuvant
Michael S. Sabel and Vernon K. Sondak
allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma . Ann Surg Oncol 2002 ; 9 : 486 – 492 . 47 Sondak VK Liu PY Tuthill RJ . Adjuvant immunotherapy of resected, intermediate-thickness, node
Leslie A. Fecher and Keith T. Flaherty
melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine . Ann Surg 1992 ; 216 : 463 – 482 . 41 Sondak V Liu P Tuthill R . Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an
Presented by: Valencia D. Thomas, Michael K. Wong, and Andrew J. Bishop
. Wong, several ongoing trials are evaluating the role of adjuvant immunotherapy in stage III disease and advanced MCC (ClinicalTrials.gov identifiers: NCT04291885 , NCT02196961 , NCT03798639 , NCT03271372 ). Although much of these data are not yet
Jane E. Rogers, Allison Trail, and Jaffer A. Ajani
approaches (meaning using residual cancer in the surgical specimen to derive an individualized vaccine or a vaccine that would address multiple antigens, adjuvant immunotherapies, bispecific antibodies, bispecific T-cell engagers, antibody drug conjugates
Alice Zhou, Omar Butt, Michael Ansstas, Elizabeth Mauer, Karam Khaddour, and George Ansstas
extending to the peripheral margin with 3 of the 9 excised lymph nodes positive for metastatic disease. Initial treatment included 30 Gy of hypofractionated radiotherapy followed by adjuvant immunotherapy with nivolumab, 480 mg every 4 weeks. After 4
Alessia Buglioni, Ruifeng Guo, Kandelaria M. Rumilla, Mark A. Edgar, Svetomir N. Markovic, and Gang Zheng
between LCH and melanoma when occurring together, with or without a shared BRAF pathogenic alteration. After surgery, the patient was treated with local radiotherapy. The oncology team planned on treating him with adjuvant immunotherapy, anti–PD-1, for
Justin Famoso, Gerald Lemole, Srinath Sundararajan, and Baldassarre Stea
maximal safe resection followed by focal radiation and adjuvant immunotherapy is both safe and effective. References 1. Wendel C , Kaech DL , Woodtli M . Primary malignant melanoma in the pineal region: case report and literature review . J
Page:12
